Consensus Rating1
Outperform
Highest Price Target1
$23.00
Lowest Price Target1
$10.00
Consensus Price Target1
$14.63

want to know what
the Bulls & Bears Say?

Profound Medical (NASDAQ:PROF) Stock, Analyst Ratings, Price Targets, Forecasts

Profound Medical Corp has a consensus price target of $14.63 based on the ratings of 7 analysts. The high is $23 issued by Raymond James on February 22, 2022. The low is $10 issued by Jefferies on March 21, 2023. The 3 most-recent analyst ratings were released by Stifel, Alliance Global Partners, and Stifel on July 16, 2024, March 11, 2024, and March 8, 2024, respectively. With an average price target of $10.6 between Stifel, Alliance Global Partners, and Stifel, there's an implied 6.00% upside for Profound Medical Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Mar
0
0
0
0
Jul
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.7
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Stifel
Alliance Global Partners
TD Cowen
Jefferies
Cowen & Co.

1calculated from analyst ratings

Analyst Ratings for Profound Medical

Buy NowGet Alert
07/16/2024Buy Now20%Stifel
Rick Wise
$9 → $12UpgradeHold → BuyGet Alert
03/11/2024Buy Now8%Alliance Global Partners
Ben Haynor
$12.75 → $10.8MaintainsBuyGet Alert
03/08/2024Buy Now-10%Stifel
Rick Wise
$11 → $9MaintainsHoldGet Alert
01/04/2024Buy Now27.5%Alliance Global Partners
Ben Haynor
$14.25 → $12.75MaintainsBuyGet Alert
11/28/2023Buy Now10%Stifel
Rick Wise
→ $11Initiates → HoldGet Alert
08/04/2023Buy NowRaymond James
Rahul Sarugaser
DowngradeStrong Buy → OutperformGet Alert
05/11/2023Buy Now80%TD Cowen
Joshua Jennings
$14 → $18MaintainsOutperformGet Alert
05/11/2023Buy Now57.5%Alliance Global Partners
Ben Haynor
$13.15 → $15.75MaintainsBuyGet Alert
03/21/2023Buy NowJefferies
Michael Sarcone
$5.5 → $10DowngradeBuy → Equal-WeightGet Alert
11/04/2022Buy NowRaymond James
Rahul Sarugaser
UpgradeOutperform → Strong BuyGet Alert
03/07/2022Buy Now40%Cowen & Co.
Joshua Jennings
$28 → $14MaintainsOutperformGet Alert
02/22/2022Buy Now130%Raymond James$28 → $23DowngradeStrong Buy → OutperformGet Alert

FAQ

Q

What is the target price for Profound Medical (PROF) stock?

A

The latest price target for Profound Medical (NASDAQ:PROF) was reported by Stifel on July 16, 2024. The analyst firm set a price target for $12.00 expecting PROF to rise to within 12 months (a possible 20.00% upside). 6 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Profound Medical (PROF)?

A

The latest analyst rating for Profound Medical (NASDAQ:PROF) was provided by Stifel, and Profound Medical upgraded their buy rating.

Q

When was the last upgrade for Profound Medical (PROF)?

A

The last upgrade for Profound Medical Corp happened on July 16, 2024 when Stifel raised their price target to $12. Stifel previously had a hold for Profound Medical Corp.

Q

When was the last downgrade for Profound Medical (PROF)?

A

The last downgrade for Profound Medical Corp happened on August 4, 2023 when Raymond James changed their price target from N/A to N/A for Profound Medical Corp.

Q

When is the next analyst rating going to be posted or updated for Profound Medical (PROF)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Profound Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Profound Medical was filed on July 16, 2024 so you should expect the next rating to be made available sometime around July 16, 2025.

Q

Is the Analyst Rating Profound Medical (PROF) correct?

A

While ratings are subjective and will change, the latest Profound Medical (PROF) rating was a upgraded with a price target of $9.00 to $12.00. The current price Profound Medical (PROF) is trading at is $10.00, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.